Key Highlights from ECTRIMS 2024

Announcer Intro:
You’re listening to NeuroFrontiers on ReachMD. On today’s episode, the President of the European Committee for Treatment and Research in Multiple Sclerosis, also known as ECTRIMS, Dr. Mar Tintoré is joining us. She also serves as the Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain. She’ll talk about highlights from this year’s ECTRIMS conference. Here she is now.

Dr. Tintore:
So this year we are expecting 9,000 participants from all over the world. We’re going to have the opportunity to discuss for three days, which are the hot topics, which are the new, expected results of clinical trials—and this is going to be the 40th anniversary of the ECTRIMS meeting—so a lot of things happening in Copenhagen this year.

So we are going to have a pre-day dedicated to pediatric MS, to neuromyelitis optica, to MOGAD, and also to other autoimmune diseases that are now rising because of the use of our immune system as a therapy for oncology. So there’s all sort of new diseases arising that have a lot in common with MS and autoimmune diseases.

Other hot topics, of course, aging. If you look at the mean age of our population of patients, this mean age is around 50 or 55, so we have a huge number of patients that are becoming older, and we need to face this disease when people get older because the treatments are not the same. And during the late-breaking news session, which typically, takes place on the last day of ECTRIMS, we will have the possibility to listen to the results of two very important phase 3 studies. This is also going to be very exciting, both for all the MS community. 

Announcer Outro:
That was Dr. Mar Tintoré giving us a preview of ECTRIMS 2024. To access this and other episodes in our series, visit NeuroFrontiers on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!